Harvard Bioscience (HBIO) Reports Q4 EPS of $0.02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Harvard Bioscience Announces Fourth Quarter 2021 Financial Results
March 8, 2022 7:00 AM ESTRevenue up 7% year-over-year as sales momentum continues, despite global supply chain headwindsGross margin improves to 59% in Q4 driven by strengthening product mix, improved operating leverage
HOLLISTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the Company) today announced financial results for the period ended December 31, 2021.
Jim Green, Chairman and CEO said, The positive trends we reported through the first three quarters of 2021 have carried through with our strong top line performance in Q4. Demand for our pre-clinical products continued to... More
